Korean J Urol.  2011 Jan;52(1):9-12.

Clinical Features of Familial or Hereditary Prostate Cancer in Korean Men: A Pilot Study

• Lee SH
• Park KK
• Chung MS
• Chung BH

Abstract

PURPOSE
There are few data regarding the epidemiology of hereditary or familial prostate cancer (PCa) in East Asians, especially in Korean men. Therefore, we evaluated the incidence of familial and hereditary PCa and the relation between socioeconomic status and the incidence of nonsporadic prostate cancer (NSPC).
MATERIALS AND METHODS
We collected data from all patients who were treated for PCa at our center between November 2009 and January 2010. All patients were either newly diagnosed or had been diagnosed with PCa and seen as outpatients during the study period.
RESULTS
In a sample of 218 patients with PCa; 25 (11.5%) were NSPC patients, and 193 (88.6%) were sporadic PCa sporadic prostate cancer (SPC) patients. Overall, 11.5% of the patients had a positive family history. There was one hereditary PCa family (three patients, 1.4%) and 11 familial PCa families (22 patients, 10.1%). Patients were divided into three different age groups. Of these, 18 (9.3%) SPC patients and 6 (24%) NSPC patients were diagnosed with the disease at the age of 55 years or younger (p=0.02). Prostate-specific antigen (PSA) levels in the NSPC group were significantly higher than in the SPC group (7.2+/-3.2 versus 6.3+/-4.9 ng/ml, p=0.042). SPC patients had larger waist circumferences than did NSPC patients (p=0.041). There were no significant differences between the SPC and NSPC groups in terms of socioeconomic status, Gleason score, pathological stage, or pathologic Gleason grade.
CONCLUSIONS
East Asian NSPC patients are diagnosed at earlier ages than are SPC patients, even though the incidence of NSPC in the East Asian population is lower than in Western men.

Keyword

Epidemiology; Prostatic neoplasms; Siblings

MeSH Terms

Asian Continental Ancestry Group
Humans
Incidence
Male
Neoplasm Grading
Outpatients
Passive Cutaneous Anaphylaxis
Pilot Projects
Prostate
Prostate-Specific Antigen
Prostatic Neoplasms
Siblings
Social Class
Waist Circumference
Prostate-Specific Antigen
Prostatic Neoplasms

Reference

1. Kiemeney LA, Broeders MJ, Pelger M, Kil PJ, Schröder FH, Witjes JA, et al. Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer. 2008. 122:871–876.

2. Aprikian AG, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, et al. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol. 1995. 154:404–406.

3. Sacco E, Prayer-Galetti T, Pinto F, Ciaccia M, Fracalanza S, Betto G, et al. Familial and hereditary prostate cancer by definition in an italian surgical series: clinical features and outcome. Eur Urol. 2005. 47:761–768.

4. Cussenot O, Valeri A, Meria P, Berthon P, Fournier G, Teillac P, et al. Genetic aspects in cancers of the prostate. Pathol Biol (Paris). 1996. 44:737–743.

5. Valeri A, Azzouzi R, Drelon E, Delannoy A, Mangin P, Fournier G, et al. Early-onset hereditary prostate cancer is not associated with specific clinical and biological features. Prostate. 2000. 45:66–71.

6. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA. 1992. 89:3367–3371.

7. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003. 91:789–794.

8. Zeegers MP, Jellema A, Ostrer H. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma: a meta-analysis. Cancer. 2003. 97:1894–1903.

9. Korea NSO. Annual report on the cause of death statistics (based on vital registration). 2007. Daejeon: National Statistical Office in Korea.

10. Kupelian PA, Reddy CA, Reuther AM, Mahadevan A, Ciezki JP, Klein EA. Aggressiveness of familial prostate cancer. J Clin Oncol. 2006. 24:3445–3450.

11. Lee KL, Marotte JB, Ferrari MK, McNeal JE, Brooks JD, Presti JC Jr. Positive family history of prostate cancer not associated with worse outcomes after radical prostatectomy. Urology. 2005. 65:311–315.

12. Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schröder FH. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol. 2006. 175:1332–1336.

13. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998. 20:175–179.

14. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet. 1999. 64:776–787.

15. Kim SH, Cho KS, Han KS, Joung JY, Seo HK, Chung J, et al. Familial prostate cancer in three brothers. Korean J Urol. 2009. 50:195–198.

16. MacInnis RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Causes Control. 2006. 17:989–1003.

17. Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol. 2007. 178:1939–1944.

18. Jackson MD, Walker SP, Simpson CM, McFarlane-Anderson N, Bennett FI, Coard KC, et al. Body size and risk of prostate cancer in Jamaican men. Cancer Causes Control. 2010. 21:909–917.

19. Zilli T, Chagnon M, Van Nguyen T, Bahary JP, Guay JP, Dufresne A, et al. Influence of abdominal adiposity, waist circumference, and body mass index on clinical and pathologic findings in patients treated with radiotherapy for localized prostate cancer. Cancer. 2010. Epub ahead of print.

20. Valeri A, Cormier L, Moineau MP, Cancel-Tassin G, Azzouzi R, Doucet L, et al. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol. 2002. 168:483–487.